AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer.
Dr Hartman will bring his significant knowledge in preclinical development and manufacturing for scale up to this newly created COO role.
Prior to joining AdAlta, Dr Hartman has held a 20 year career in drug development, and was most recently Vice President of Product Development for NASDAQ-listed Nexvet Biopharma (NASDAQ: NVET), a company focused on developing and commercialising novel biologic therapies for companion animals. Prior to that role, Dr Hartman was Director
of Analytical Biochemistry for CSL.
AdAlta’s CEO, Sam Cobb said Dr Hartman had extensive experience and would provide a valuable addition to the focused AdAlta team. “Dallas will play a crucial role as we progress
our current pre-clinical program through the early stages of regulatory approval and partnering.”
Dr Hartman commences in the role of COO on 9th October 2017.
